Patents by Inventor Kulandayan Kasi Subramanian

Kulandayan Kasi Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE REGIMES FOR ANTI-CD73 AND ANTI-ENTPD2 ANTIBODIES AND USES THEREOF
    Publication number: 20240141060
    Abstract: The invention generally relates to dosage regimes of anti-Cluster of Differentiation 73 (CD73) antibodies and/or anti-ectoenzyme ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) antibodies, used in methods of treatment of cancer in a subject, as well as dosage regimes of anti-CD73 antibodies for use in treating cancer. The invention further generally relates to dosage regimes of combinations of agents, such as combinations comprising anti-CD73 antibodies and/or anti-ENTPD2 antibodies and at least one or more of a PD-1 inhibitor, and an adenosine A2AR antagonist.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 2, 2024
    Inventors: Juan Gonzalez-Maffe, Randi Ellen Isaacs, Jaeyeon Kim, Lisa Nardi, Javier Alberto Otero, Nehal Parikh, Michael John Roy, Kulandayan Kasi Subramanian, Tingting Zhai
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20230039109
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: February 9, 2023
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Helena Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, III, Michael Gladstone, Jonathan Hill, Christine Miller
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20210214459
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Inventors: Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, John Delmas Venable, III, Bianka Prinz, Jerry M. Thomas, Andrew Lake, Scott Chappel, Pamela Holland, Michael Warren, Alison Paterson, Rachel W. O'Connor, Michael Gladstone, Jonathan Hill, Christine Miller
  • Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
    Publication number: 20210147547
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventors: Andrew Marc Stein, Kulandayan Kasi Subramanian
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20190031766
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: June 21, 2018
    Publication date: January 31, 2019
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chapel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable III